Effects of Acetyl-DL-Leucine on Ataxia and Downbeat-Nystagmus in Six Patients With Ataxia Telangiectasia

Abstract

Background:

There is no authorized treatment for ataxia telangiectasia (AT). As cerebellar symptoms of storage diseases were improved by acetyl-DL-leucine (ADLL), the authors hypothesized a symptomatic and disease-modifying effect in AT upon supplementation with ADLL.

Methods:

Six patients were treated with ADLL 3 g/day for 1 week followed by 5g/day for 3 weeks to 1 year. Cerebellar ataxia was evaluated by validated scales. Gaze-holding, saccades and smooth pursuit were examined by video-oculography. Measurements took place at baseline, at 1 month of therapy in 5 patients, and after 6 and 12 months in 1 patient.

Results:

The Scale for Assessment and Rating of Ataxia changed from the baseline, mean, (SD, min-max) of 22.1 (5.88, 11-28.5) to 18 points (5.39, 8.5-23.5) after 1 month on medication (P = .0028). All patients demonstrated gaze-holding deficits; 3 patients had central-position downbeat-nystagmus. Mean slow-phase velocity of this nystagmus with the gaze straight-ahead changed from 5.57°/s (1.8, 3.53-6.99) to 4.7°/s (0.79, 3.97-5.56) after 1 month on treatment (1.35, -2.56-4.17) (P = .046).

Interpretation:

ADLL may improve ataxia and ocular stability in AT patients, while the molecular basis still remains to be elucidated. A multicentric, rater-blinded, phase II trial currently investigates the effects of acetyl-L-leucine in AT (NCT03759678).

Keywords

ataxia cerebellum quality of life pediatric neurodevelopment

Get full access to this article

View all access options for this article.

References

Rotman

Shiloh

. Ataxia-telangiectasia: is ATM a sensor of oxidative damage and stress? Bioessays. 1997;19(10):911–917.

NJH van

Haaxma

der

Flier M van

, et al. Ataxia-telangiectasia: recommendations for multidisciplinary treatment. Dev Med Child Neurol. 2017;59(7):680–689.

Shiloh

Ziv

. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013;14(4):197–210.

Woods

Taylor

. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. Q J Med. 1992;82(298):169–179.

Tang

Shaikh

. Past and present of eye movement abnormalities in ataxia-telangiectasia. Cerebellum. 2019;18(3):556–564.

Shaikh

Marti

Tarnutzer

, et al. Ataxia telangiectasia: a “disease model” to understand the cerebellar control of vestibular reflexes. J Neurophysiol. 2011;105(6):3034–3041.

Shaikh

Marti

Tarnutzer

, et al. Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia. J Neurol. 2013;260(11):2728–2735.

Gatti

Becker-Catania

Chun

, et al. The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clin Rev Allergy Immunol. 2001;20(1):87–108.

Rothblum-Oviatt

Wright

Lefton-Greif

McGrath-Morrow

Crawford

Lederman

. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016;11(1):159.

10.

Bremova

Malinová

Amraoui

, et al. Acetyl-dl-leucine in Niemann-Pick type C: A case series. Neurology. 2015;85(16):1368–1375.

11.

Bremova-Ertl

Platt

Strupp

. Sandhoff-disease: improvement of gait by acetyl-DL-leucine—a case report. Neuropediatr. 2020;51(6):450–452.

12.

Anheim

Tranchant

Koenig

. The autosomal recessive cerebellar ataxias. N Engl J Med. 2012;366(7):636–646.

13.

Subramony

. SARA—a new clinical scale for the assessment and rating of ataxia. Nat Clin Pract Neurol. 2007;3(3):136–137.

14.

Schmitz-Hübsch

du Montcel

Baliko

, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66(11):1717–1720.

15.

Schmitz-Hübsch

Giunti

Stephenson

, et al. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology. 2008;71(7):486–492.

16.

Nasreddine

Phillips

Bédirian

, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699.

17.

Devlin

Brooks

. EQ-5D and the EuroQol group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127–137.

18.

Schneider

Villgrattner

Vockeroth

, et al. EyeSeeCam: an eye movement-driven head camera for the examination of natural visual exploration. Ann NY Acad Sci. 2009;1164(1):461–467.

19.

López-Bastida

Perestelo-Pérez

Montón-Alvarez

Serrano-Aguilar

. Social economic costs and health-related quality of life in patients with degenerative cerebellar ataxia in Spain. Mov Disord. 2008;23(2):212–217.

20.

Vibert

Vidal

. In vitro effects of acetyl-DL-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig. Eur J Neurosci. 2001;13(4):735–748.

21.

de Waele

Vidal

Tran Ba Huy

Freyss

Vestibular compensation. Review of the literature and clinical applications. Ann Otolaryngol Chir Cervicofac. 1990;107:285–298.

22.

Ferber-Viart

Dubreuil

Vidal

. Effects of acetyl-DL-leucine in vestibular patients: a clinical study following neurotomy and labyrinthectomy. Audiol Neurootol. 2009;14(1):17–25.

23.

Günther

Beck

Xiong

, et al. N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus. PLOS ONE. 2015;10(3): e0120891.

24.

Kaya

Smith

, et al. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun. 2020;3(1):fcaa148.

25.

Spiegel

Kalla

Rettinger

, et al. Head position during resting modifies spontaneous daytime decrease of downbeat nystagmus. Neurology. 2010;75(21):1928–1932.

26.

Spiegel

Rettinger

Kalla

, et al. The intensity of downbeat nystagmus during daytime. Ann NY Acad Sci. 2009;1164:293–299.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

111.32 MB